Browse the evidence

Weekly subcutaneous Semaglutide 2.4 mg results in a -13.7% body weight reduction.

Practitioners may consider Semaglutide as an effective weight loss therapy for women with preeclampsia.

Carbohydrate restriction leads to appetite reduction, weight loss, and improvements in glycemic and insulin control.

Practitioners may consider carbohydrate restriction as a strategy for managing obesity and T2DM.

Participants demonstrated significant changes in eating habits, including increased vegetable and fruit consumption.

Encouraging healthier eating habits is essential for successful weight management.

Lifestyle changes may impact cardiovascular outcomes in type 2 diabetes.

Encouraging lifestyle changes may be beneficial for cardiovascular health in patients with type 2 diabetes.

Health coaching significantly reduced menopausal symptoms in postmenopausal and perimenopausal women, with a mean difference of -12.51 in menopausal scores from baseline to 4 months after the intervention.

Health coaching can be an effective intervention for reducing menopausal symptoms in women.

Health coaching improved quality of life in postmenopausal and perimenopausal women, with a mean difference of 4.13 from baseline to 4 months.

Health coaching can enhance the quality of life for women experiencing menopause.

Evidenzbasierte Therapieoptionen bei AP-assoziierter Gewichtszunahme umfassen Lebensstilveränderungen, Bewegungstherapie und medikamentöse Anpassungen.

Implementing lifestyle changes and considering medication adjustments can help manage weight gain in patients.

Evidenzbasierte Therapieoptionen bei AP-assoziierter Gewichtszunahme umfassen Lebensstilveränderungen, diätetische Maßnahmen, Bewegungstherapie, Dosisreduktion, Umstellung und Beendigung der Medikation sowie zusätzliche Therapien.

Implementing lifestyle and dietary changes can be effective in managing weight gain from medications.

A 10-minute daily yoga practice was significantly associated with changes in menstrual cycle symptoms and has the potential to mitigate some menstrual cycle symptoms and stress perception in an athletic cohort.

Incorporating a short daily yoga routine may help athletic women manage menstrual symptoms and stress.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces clinically significant weight loss (mean 6.2–12.9 kg) and glycemic control (HbA1c reduction -1.87 to -2.59%) in adults with type 2 diabetes, with efficacy increasing with dose up to 15 mg weekly.

Tirzepatide is a once-weekly injection for type 2 diabetes that helps lower blood sugar and lose weight. It starts at a low dose (2.5 mg) to minimize side effects like nausea, which usually improve over time. The dose can be increased every 4 weeks up to 15 mg based on tolerance and need. It is approved for adults with T2DM, especially those who are overweight or obese, and works by mimicking hormones that regulate blood sugar and appetite. Patients should follow dietary advice (smaller, low-fat meals) to manage GI side effects and monitor blood glucose, especially if taking other diabetes medications like insulin or sulfonylureas.

Tirzepatid (GIP/GLP-1 agonist) provides superior weight loss and glycemic control compared to Semaglutid in patients with Type 2 Diabetes and Obesity.

If oral medications and lifestyle changes are insufficient, Tirzepatid (10-15mg weekly) is currently the most effective pharmacological option for weight loss and blood sugar control in Type 2 Diabetes, outperforming Semaglutid. Discuss this with your doctor to see if it's appropriate for your specific health profile.

GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors (e.g., Empagliflozin, Canagliflozin) significantly reduce cardiovascular risk and mortality in type 2 diabetic patients with high cardiovascular risk factors.

For T2D patients with high cardiovascular risk, GLP-1 receptor agonists (Semaglutide, Liraglutide) and SGLT-2 inhibitors (Empagliflozin, Canagliflozin) are superior to standard treatments for preventing heart attacks, strokes, and cardiovascular death. These drugs offer significant mortality benefits.

Semaglutide (2.4 mg weekly) and Liraglutide (3.0 mg daily) are effective pharmacological adjuncts for obesity, producing significant weight loss (15% and 8-10% respectively) when combined with lifestyle interventions.

For patients with BMI ≥ 30 (or ≥ 25 with comorbidities) who do not achieve goals with lifestyle changes alone, consider GLP-1 analogues. Semaglutide 2.4mg weekly yields ~15% weight loss; Liraglutide 3mg daily yields ~8-10%. These are adjuncts to, not replacements for, behavioral therapy.

Intentional weight loss via GLP-1 receptor agonists (liraglutide, semaglutide) and SGLT2 inhibitors (empagliflozin) reduces cardiovascular events and mortality in type 2 diabetes patients, contradicting the 'obesity paradox' which suggests higher BMI is protective.

If you have Type 2 Diabetes, medications like GLP-1 agonists (e.g., liraglutide, semaglutide) or SGLT2 inhibitors (e.g., empagliflozin) are proven to help your heart and reduce weight. Do not rely on the 'obesity paradox' to justify carrying excess weight; these drugs actively reduce cardiovascular risk and mortality.

Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly semaglutide injections, combined with diet and exercise, can lead to significant weight loss (around 10%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.

If you have obesity or overweight with related health issues, daily liraglutide injections, combined with diet and exercise, can lead to moderate weight loss (around 5 kg) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated. Note that it may be less effective than other options like semaglutide.

Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.

Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.

Aggressive LDL cholesterol lowering with high-dose statins (e.g., atorvastatin 80mg) significantly reduces major cardiovascular events and induces regression of coronary atherosclerosis in patients with type 2 diabetes, even when baseline LDL levels are within normal ranges.

If you have Type 2 Diabetes, your risk of heart disease is significantly higher than the general population. Current medical guidelines recommend statin therapy for most diabetic patients, regardless of whether your cholesterol numbers look 'normal' on a standard test. Aggressive treatment with high-dose statins (like atorvastatin 80mg) is proven to shrink existing plaque in your arteries and significantly reduce your risk of heart attack and stroke. This is a primary prevention strategy that should be discussed with your doctor, especially if you have other risk factors like high blood pressure or smoking history.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular protection and should be prioritized in women with type 2 diabetes and high cardiovascular risk.

If you have diabetes and heart risk factors, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs protect your heart and kidneys beyond just lowering blood sugar. Standard sugar-lowering pills may not be enough for heart protection.

A semi-mechanistic exposure-response model using semaglutide 2.4 mg once weekly can accurately predict individual 1-year weight loss outcomes based on baseline demographics and early weight data (up to 28 weeks).

If you are starting semaglutide 2.4 mg, do not judge the treatment's effectiveness solely on your weight at week 0 or even week 4. The model shows that predictions become highly accurate (MAE ~3kg) only after incorporating weight data from weeks 8, 16, or 28. Use early weigh-ins to recalibrate expectations with your doctor rather than stopping treatment prematurely due to perceived lack of efficacy.

For individuals with type 2 diabetes, a Mediterranean diet provides superior glycemic control (fasting glucose and insulin sensitivity) compared to a low-fat diet.

If you have type 2 diabetes, a Mediterranean diet may help control your blood sugar better than a standard low-fat diet. This diet emphasizes vegetables, olive oil, and nuts, and limits red meat. In this study, it significantly improved insulin sensitivity and lowered fasting glucose in diabetic participants, whereas a low-fat diet did not.

Combining naltrexone SR (32 mg/day) and bupropion SR (360 mg/day) with intensive behavior modification produces significantly greater weight loss (9.3%) and cardiometabolic improvements compared to behavior modification alone (5.1%) in obese adults over 56 weeks.

If you have obesity, adding this specific combination of naltrexone and bupropion to a structured diet and exercise program can nearly double your average weight loss compared to diet and exercise alone. The medication is taken twice daily and requires a slow start to minimize nausea. It is most effective for those without diabetes or heart conditions.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle interventions, produces substantial and sustained weight loss (mean 14.9% at 68 weeks) and improves cardiometabolic risk factors in adults with overweight or obesity.

If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg combined with a modest calorie deficit and regular exercise can lead to significant, sustained weight loss (around 15% on average) and better heart health markers. Start with the lowest dose to minimize stomach upset, and expect side effects like nausea to fade over time.